Why Is Gene Therapy Focused Senti Bio Stock Falling Today?

Benzinga_recent_news12-10

On Tuesday, Senti Biosciences, Inc. (NASDAQ:SNTI) shared new data from its ongoing trial of SENTI-202, a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy in patients with relapsed or...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2590326220?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-10 02:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2590326220","market":"us","top_or_hot":-1,"title":"Why Is Gene Therapy Focused Senti Bio Stock Falling Today?","media":"Benzinga_recent_news","content":"<div>\n<p>On Tuesday, Senti Biosciences, Inc. (NASDAQ:SNTI) shared new data from its ongoing trial of SENTI-202, a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy in patients with relapsed or...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Is Gene Therapy Focused Senti Bio Stock Falling Today?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Is Gene Therapy Focused Senti Bio Stock Falling Today?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-10 02:34 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On Tuesday, Senti Biosciences, Inc. (NASDAQ:SNTI) shared new data from its ongoing trial of SENTI-202, a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy in patients with relapsed or...</p>\n\n<a href=\"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","article_id":"2590326220","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/09/Gene-therapy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/25/12/49288255/why-is-gene-therapy-focused-senti-bio-stock-falling-today","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590326220","pubTimestamp":1765305240,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Senti Bio reports encouraging SENTI-202 AML trial results as the FDA grants RMAT status, with strong response rates, durable remissions, and a favorable safety profile.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","SNTI":"Senti Biosciences, Inc.","ORR":"Militia Long/Short Equity ETF","BK4139":"生物科技","ASH":"Ashland","BK4161":"工业机械","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","CR":"crane","BK4109":"特种化学制品"},"translate_title":"为什么专注于基因治疗的Senti Bio股票今天下跌？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNTI":1,"ASH":1,"ORR":1,"CR":1},"content_text":"On Tuesday, Senti Biosciences, Inc. (NASDAQ:SNTI) shared new data from its ongoing trial of SENTI-202, a first-in-class CD33/FLT3 targeting Logic Gated CAR NK cell therapy in patients with relapsed or refractory Acute Myeloid Leukemia.\nData from 20 patients (18 with evaluable responses) were presented at the American Society of Hematology (ASH) Annual Meeting.\nOn Tuesday, the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202.\n50% (6/12) of patients at the Recommended Phase 2 Dose (RP2D) and 50% (9/18) of all trial patients achieved an Overall Response Rate (ORR) outcome.\n42% (5/12) of patients at the RP2D and 39% (7/18) of all patients overall achieved a Complete Remission (CR) or CR with Partial Hematologic Recovery (CRh).\n100% of all CRs and ~80%+ of all responses were minimal residue disease (MRD) negative.\nWith limited follow-up in the RP2D cohort, the Kaplan-Meier estimate of median duration of composite Complete Remissions across all patients is 7.6 months.\nLongest durability of response greater than 1 year and continuing as of the data cut-off date.\nPharmacodynamic data validate SENTI-202’s OR/NOT Logic Gate mechanism of action for selectively killing AML blasts and leukemic stem cells (LSCs) while sparing healthy hematopoietic stem and progenitor cells (HSPCs).\nSENTI-202 continues to be well-tolerated, with no dose-limiting toxicities, no SENTI-202-related serious adverse events, or adverse events resulting in discontinuation.\nSENTI-202 was detected in the peripheral blood of all patients, with pharmacokinetics that were consistent with other allogeneic NK cell therapies: expansion in the peripheral blood for the first 2 weeks followed by natural clearance.\nSENTI-202’s clinical responses show that the product has conferred meaningful clinical benefits to a heavily pretreated patient population.\nSNTI Price Action: Senti Biosciences shares were down 16.73% at $1.99 at the time of publication on Tuesday, according to Benzinga Pro data.\nRead Next:\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2590326220","isCrawlerRequest":true}